Gilbert Lynn Marks's most recent trade in AN2 Therapeutics Inc was a trade of 19,111 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on May 22, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Gilbert Lynn Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2025 | 19,111 | 19,111 | - | - | Stock Option (Right to Buy) | |
| AN2 Therapeutics Inc | Gilbert Lynn Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Apr 2025 | 9,705 | 41,507 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Lynn Marks Gilbert | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Dec 2024 | 8,972 | 31,802 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Gilbert Lynn Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Jun 2024 | 64,503 | 64,503 | - | - | Stock Option (Right to Buy) | |
| AN2 Therapeutics Inc | Gilbert Lynn Marks | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2022 | 10,362 | 10,362 | - | - | Stock Option (right to buy) |